Two new intranasal drugs slow inflammation and stop the spread of alpha-synuclein in mouse models of Parkinson's disease. The drug also improved gait and balance in the animals. If the results are able to be replicated in humans, researchers say the drugs could be hailed as a "remarkable advance" in the treatment of Parkinson's disease.
Study reveals a direct link between adherence to the Mediterranean diet and improved cognitive function.
Higher glucose levels detected by a two-hour glucose test were an accurate predictor of poorer performance in tests of episodic memory ten years later.
Cellular reprogramming of glioma cells into neural cells may be a promising treatment for glioblastoma brain cancer.
A new algorithm uses neuroimaging data of amyloid levels in the brain and takes into account a person's age to determine when a person with genetic Alzheimer's risk factors, and with no signs of cognitive decline, will develop the disease.
Stem cell study reveals astrocytes carrying the Alzheimer's associated APOE4 gene release more cholesterol than those carrying the APOE3 gene. Findings shed light on how different versions of the APOE gene in astrocytes influence amyloid-beta production and how the oversupply of cholesterol associated with APOE4 astrocytes may promote amyloid-beta formation in Alzheimer's patients.
Cholesterol produced by astrocytes in the brain is required for the production of amyloid-beta. The findings shed light on how and why amyloid-beta forms, and may explain why genes associated with cholesterol have been implicated as risk factors for Alzheimer's disease.
Amyloid-beta proteins created in the liver are carried in the blood by lipoproteins to the brain. This results in neurodegeneration, brain atrophy, and inflammation, which are common features of Alzheimer's disease.
A new bio-inspired slow-release system for site 1 sodium channel blockers helps release anesthesia, providing prolonged nerve blocking with minimal toxicity.